PRESS RELEASE published on 01/16/2025 at 07:00, 1 year 5 months ago Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital Innate Pharma releases shares and voting rights update as of December 31, 2024, in compliance with regulations. Learn more about the global biotech company's innovative immunotherapies for cancer patients Voting Rights Shares Biotechnology Immunotherapy Innate Pharma
BRIEF published on 12/20/2024 at 07:05, 1 year 6 months ago Innate Pharma à la 43ème J.P. Morgan Healthcare Conference Investisseurs Présentation En Direct Immunothérapie Innate Pharma J.P. Morgan Conference
BRIEF published on 12/20/2024 at 07:05, 1 year 6 months ago Innate Pharma at the 43rd JP Morgan Healthcare Conference Investors Immunotherapy Innate Pharma JP Morgan Conference Live Presentation
PRESS RELEASE published on 12/20/2024 at 07:00, 1 year 6 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à la 43ème J.P. Morgan Healthcare Conference avec présentations de ses dirigeants. Focus sur les traitements d'immunothérapies contre le cancer Cancer Innate Pharma Biotechnologies Immunothérapies J.P. Morgan Healthcare Conference
PRESS RELEASE published on 12/20/2024 at 07:00, 1 year 6 months ago Inside Information / Other news releases Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference with CEO Jonathan Dickinson and other executives presenting. Company focuses on developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients J.P. Morgan Healthcare Conference
BRIEF published on 12/06/2024 at 07:05, 1 year 6 months ago Innate Pharma : Investissement de 7,9 millions de dollars pour IPH6501 Investissement Essai Clinique Innate Pharma Lymphome Folliculaire IPH6501
BRIEF published on 12/06/2024 at 07:05, 1 year 6 months ago Innate Pharma: Investment of 7.9 million dollars for IPH6501 Investment Clinical Trial Innate Pharma IPH6501 Follicular Lymphoma
PRESS RELEASE published on 12/06/2024 at 07:00, 1 year 6 months ago Informations privilégiées / Autres communiqués Innate Pharma et l'Institut d'Innovation pour le Lymphome Folliculaire (IFLI) signent un accord d'investissement jusqu'à 7,9 millions de dollars pour le développement d'IPH6501 dans le lymphome folliculaire Investissement Innate Pharma Lymphome Folliculaire IPH6501 IFLI
BRIEF published on 11/20/2024 at 07:05, 1 year 7 months ago Innate Pharma dévoile son calendrier financier pour 2025 Résultats Annuels Innate Pharma Calendrier Financier 2025 Assemblées Et Publications Cotisation Euronext Et Nasdaq
BRIEF published on 11/20/2024 at 07:05, 1 year 7 months ago Innate Pharma unveils its financial calendar for 2025 Annual Results Innate Pharma Financial Calendar 2025 Assemblies And Publications Euronext And Nasdaq Contribution
Published on 06/27/2026 at 01:40, 3 hours 29 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 5 hours 9 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 6 hours 9 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 6 hours 19 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 6 hours 54 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 5 hours 4 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 5 hours 5 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 5 hours 33 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 5 hours 33 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 5 hours 41 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 11 hours 24 minutes ago Descriptif du programme de rachat d'actions
